AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
ID Number 80-0066-00073Principal Investigator(s)
Department(s) or Division(s)
Hematology and Oncology
The purpose of this study is:
- Compare the effects, good and/or bad, of a higher dose of oral methotrexate with the standard dose for the treatment of children with Average Risk B-precursor ALL. In this study, your child will get either the higher dose, or the standard dose of oral methotrexate. Your child will not get both.
Recruiting Patients: Yes